BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
  • Interviews
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  Business Intelligence

Five Genomics Watchpoints for 2026

by BiopharmaTrend   •   Feb. 20, 2026

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline.

The beginning of this year is already offering a couple of data points that pick up last year’s momentum and hint at where genomics might be moving next. On January 13, during JPM week, Illumina announced the Billion Cell Atlas — a genome-wide perturbation dataset built from 1B cells meant as the foundation for large-scale target validation and AI model training. With AstraZeneca, Eli Lilly, and MSD involved, the initiative was framed as an attempt to create a standardized map of gene function that could be reused across different drug discovery programs.

Just a day earlier, MIT Technology Review published its annual 10 Breakthrough Technologies list. This year, three of the highlighted technologies were in genomics: personalized gene editing, embryo scoring, and gene resurrection. From there, it seems like genomic applications are moving more into the mainstream technology discourse.

Another just-in data point from a few days ago is a report out of San Diego, where Element Biosciences says its newly announced VITARI benchtop sequencer can deliver a whole genome for $100, positioning it as a lower-cost alternative to Illumina’s high-throughput systems.


Photo: Roche’s SBX setup

Looking at these and many of last year’s developments, genomics come into view as an integrated technology wave that extends from data generation to interpretation, intervention, and biological reconstruction.

With those early-2026 pings as a starting point, let’s do a selective pass through a few genomics patterns that seem to be carrying momentum into 2026.


 

Read this Pro article free

Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.

See Pro plans

Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.

Already subscribed? Sign in here.
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook    

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar
  • Sponsored Content

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.

Sign in or create an account